Izgrev

Hydrochlorothiazide / Irbesartan, the active ingredient in Izgrev, is a thiazide diuretic and angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Izgrev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Izgrev, a combination of a thiazide diuretic and an angiotensin II receptor blocker, is indicated for conditions related to high blood pressure.

- Primary hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension requiring diuretic therapy: adds diuretic effect to improve fluid balance and blood pressure control. - Hypertension with additional cardiovascular risk: provides dual mechanism to achieve better long‑term blood pressure management.

Adverse reactions may occur with any antihypertensive therapy and should be monitored.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Increased urination: due to diuretic action, may cause nocturia. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Headache: occasional mild to moderate intensity. - Fatigue: general tiredness during treatment initiation.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss leading to hypotension. - Hyperkalemia: elevated potassium that can cause cardiac arrhythmias. - Acute renal impairment: sudden decrease in kidney function. - Angioedema: swelling of face, lips, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing fainting or shock.

Before initiating therapy, consider the following safety measures.

- Electrolyte monitoring: check serum potassium and sodium regularly. - Renal function assessment: evaluate creatinine and eGFR before and during treatment. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Pregnancy and lactation: safety not established; use only if clearly needed. - Concomitant medications: review for drugs that affect potassium or renal function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Drug interactions may modify the efficacy or safety of Izgrev.

Major Interactions (Avoid): - Lithium: increased lithium levels may cause toxicity. - ACE inhibitors or other ARBs: combined use can lead to severe hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics: risk of dangerous hyperkalemia. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia.

Moderate Interactions (Monitor Closely): - Other diuretics: may enhance electrolyte disturbances. - Beta‑blockers: additive blood pressure lowering effect; monitor for hypotension. - CYP2C9 substrates (e.g., warfarin): Irbesartan may alter plasma concentrations; adjust dosing as needed.